NCT04786028 is a Phase 2 clinical trial of Isatuximab in Multiple Myeloma, sponsored by Canadian Myeloma Research Group.

Who is sponsoring NCT04786028?

NCT04786028 is sponsored by Canadian Myeloma Research Group.

What drugs are being tested in NCT04786028?

Interventions in NCT04786028: Isatuximab.

What condition does NCT04786028 study?

NCT04786028 studies Multiple Myeloma.

Is NCT04786028 still recruiting?

NCT04786028 is currently active, enrolled. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT04786028

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

Active, enrolled Phase 2 Last updated 7 January 2025

What this trial tests

Phase 2 trial testing Isatuximab in Multiple Myeloma in 72 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 December 2021

Primary endpoint
1 March 2026

1 June 2027

Quick facts

Lead sponsor	Canadian Myeloma Research Group
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	72
Start date	8 December 2021
Primary completion	1 March 2026
Estimated completion	1 June 2027
Sites	7 locations across Canada

Drugs / interventions tested

Isatuximab (isatuximab) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Canadian Myeloma Research Group

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response rate (VGPR or better) defined by IMWG criteria
Time frame: 100 days
To determine the response rate (VGPR or better) defined by IMWG criteria at 100 days (+/- 7 days) after the autologous stem cell transplant (ASCT).

Sponsor's own description

This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, et al · · 2023 · cited 60× · PMID 36642080 · DOI 10.1016/s1470-2045(22)00738-0
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.
Ocio EM, Bringhen S, Martinez-Lopez J, Martinez-Lopez J, et al · · 2023 · cited 4× · PMID 36751513 · DOI 10.1097/hs9.0000000000000829
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma.
Tariq SM, Abdallah AO, Goodman A, Sborov D, et al · · 2023 · cited 3× · PMID 37133718 · DOI 10.1007/s44228-023-00044-8

Verify or expand the search:

Other trials of Isatuximab

Trials testing the same drug.

NCT07045909 — Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · Phase 2 · recruiting
NCT05862766 — Isatuximab in Lung Transplant Recipients · EARLY_PHASE1 · withdrawn
NCT05922501 — Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06182774 — Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu · Phase 3 · recruiting
NCT06203912 — Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Canadian Myeloma Research Group trials

Trials by the same sponsor.

NCT04258683 — A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (Cy · Phase 2 · withdrawn
NCT03697629 — A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma · Phase 2 · completed
NCT03715478 — Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex · Phase 1, PHASE2 · active not recruiting
NCT03215524 — A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04786028 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Myeloma Research Group
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04786028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing